Susquehanna International Group’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.19M | Sell |
40,058
-24,914
| -38% | -$745K | ﹤0.01% | 7437 |
|
|
2025
Q4 | $2.48M | Buy |
+64,972
| New | +$2.11M | ﹤0.01% | 5211 |
|
|
2025
Q3 | – | Sell |
-109,787
| Closed | -$2.06M | – | 13930 |
|
|
2025
Q2 | $1.62M | Sell |
109,787
-13,473
| -11% | -$223K | ﹤0.01% | 6243 |
|
|
2025
Q1 | $2.21M | Buy |
123,260
+17,215
| +16% | +$349K | ﹤0.01% | 5298 |
|
|
2024
Q4 | $1.85M | Buy |
106,045
+67,748
| +177% | +$1.2M | ﹤0.01% | 5501 |
|
|
2024
Q3 | $536K | Sell |
38,297
-66,451
| -63% | -$692K | ﹤0.01% | 8291 |
|
|
2024
Q2 | $861K | Buy |
104,748
+15,682
| +18% | +$106K | ﹤0.01% | 6934 |
|
|
2024
Q1 | $687K | Buy |
89,066
+62,215
| +232% | +$525K | ﹤0.01% | 7745 |
|
|
2023
Q4 | $241K | Sell |
26,851
-37,943
| -59% | -$276K | ﹤0.01% | 10300 |
|
|
2023
Q3 | $579K | Buy |
64,794
+4,729
| +8% | +$66.7K | ﹤0.01% | 7884 |
|
|
2023
Q2 | $923K | Sell |
60,065
-68,661
| -53% | -$1.25M | ﹤0.01% | 6871 |
|
|
2023
Q1 | $2.9M | Buy |
128,726
+82,717
| +180% | +$1.76M | ﹤0.01% | 4400 |
|
|
2022
Q4 | $968K | Sell |
46,009
-28,665
| -38% | -$607K | ﹤0.01% | 6272 |
|
|
2022
Q3 | $1.84M | Buy |
74,674
+58,468
| +361% | +$1.51M | ﹤0.01% | 5085 |
|
|
2022
Q2 | $393K | Sell |
16,206
-28,622
| -64% | -$720K | ﹤0.01% | 8847 |
|
|
2022
Q1 | $1.16M | Sell |
44,828
-24,548
| -35% | -$652K | ﹤0.01% | 6765 |
|
|
2021
Q4 | $2.15M | Buy |
69,376
+19,787
| +40% | +$557K | ﹤0.01% | 5337 |
|
|
2021
Q3 | $1.2M | Sell |
49,589
-115,985
| -70% | -$2.13M | ﹤0.01% | 7065 |
|
|
2021
Q2 | $2.42M | Buy |
165,574
+119,176
| +257% | +$2.35M | ﹤0.01% | 5491 |
|
|
2021
Q1 | $1.16M | Buy |
46,398
+27,534
| +146% | +$761K | ﹤0.01% | 7331 |
|
|
2020
Q4 | $514K | Buy |
+18,864
| New | +$440K | ﹤0.01% | 8233 |
|
|
2020
Q2 | – | Sell |
-24,536
| Closed | -$391K | – | 10955 |
|
|
2020
Q1 | $358K | Buy |
+24,536
| New | +$369K | ﹤0.01% | 7640 |
|
|
2019
Q4 | – | Sell |
-24,775
| Closed | -$316K | – | 10672 |
|
|
2019
Q3 | $287K | Sell |
24,775
-14,199
| -36% | -$235K | ﹤0.01% | 8387 |
|
|
2019
Q2 | $783K | Buy |
+38,974
| New | +$770K | ﹤0.01% | 6247 |
|
|
2015
Q4 | – | Sell |
-25,062
| Closed | -$501K | – | 10000 |
|
|
2015
Q3 | $508K | Buy |
25,062
+14,316
| +133% | +$424K | ﹤0.01% | 7094 |
|
|
2015
Q2 | $356K | Sell |
10,746
-3,224
| -23% | -$88.3K | ﹤0.01% | 8251 |
|
|
2015
Q1 | $335K | Sell |
13,970
-56,171
| -80% | -$857K | ﹤0.01% | 7775 |
|
|
2014
Q4 | $859K | Buy |
+70,141
| New | +$726K | ﹤0.01% | 6156 |
|
Other funds holding TVTX
AC
PA
VCM
NAMI
Susquehanna International Group's TVTX Position: Q1 2026 in Review
Susquehanna International Group reduced its Travere Therapeutics (TVTX) stake by 38% in Q1 2026, selling an estimated $745K and leaving 40,058 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #7437.
Susquehanna International Group first reported a position in TVTX in Q4 2014 and has held it in 28 quarters since. The position peaked at $2.9M in Q1 2023. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.
- Susquehanna International Group held 40,058 shares of Travere Therapeutics worth $1.19M as of Q1 2026.
- Susquehanna International Group sold 24,914 Travere Therapeutics shares in Q1 2026, an estimated $745K.
- Travere Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7437 holding.
- Susquehanna International Group first reported a position in Travere Therapeutics in Q4 2014 and has held it in 28 quarters since.
- Susquehanna International Group's Travere Therapeutics position peaked at $2.9M in Q1 2023.
- 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.